Close Menu

Catherine Friedman, Alex Aravanis

Dec 11, 2018

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She has also held numerous executive positions during her investment banking career with Morgan Stanley, including as managing director and head of West Coast healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as CSO and head of R&D. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of R&D for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

More Like This

Mar 05, 2021

Quidel: Joseph Wilkins

Quidel has expanded the size of its board of directors from nine to ten members and appointed Joseph Wilkins to the board.

Wilkins is a partner at healthcare consulting firm TRG Healthcare, a limited partner at privately-held venture capital fund Tech Council Ventures, and is an advisor with Touchdown Ventures, a privately held venture capital group. He previously served as senior vice president and chief transformation and innovation officer for Atlantic Health System, an integrated healthcare delivery system, and prior to that he held positions at Quest Diagnostics and Danaher subsidiary Beckman Coulter.

Mar 05, 2021

Prometheus Biosciences: Mark Stenhouse

Prometheus Biosciences, a developer of therapeutic and companion diagnostic products for inflammatory bowel disease, has appointed Mark Stenhouse as chief operating officer. Stenhouse previously served as general manager of the screening business at Exact Sciences. He previously spent nearly 30 years at Abbott Laboratories/AbbVie, most recently as vice president of US immunology. He was also vice president and general manager of the gastroenterology franchise, having spent 10 years working in IBD. Stenhouse currently is a member of the board of directors for Phathom Pharmaceuticals.

Mar 04, 2021

Precipio: Ron Andrews

Precipio has announced that Ron Andrews has joined the company's board of directors. In addition to currently serving as CEO of molecular diagnostics firm OncoCyte, Andrews' past experiences include a term as CEO of Roche Molecular, president of the genetic science division at Thermo Fisher Scientific, president of the medical sciences venture at Life Technologies, and CEO of Clarient.

Mar 03, 2021

Geneoscopy: Vince Wong

Geneoscopy has appointed Vince Wong as it chief commercial officer. Wong previously served as VP of sales at Roche Diagnostics. He has also served as VP and general manager of physician office and specialty diagnostics at the firm. 

Mar 03, 2021

Transplant Genomics: Nicholas Grund, John Slaught, Charles Argentine

Transplant Genomics has appointed Nicholas Grund as president, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.

Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long-term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.

Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada. 

Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.

Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.

Feb 25, 2021

Quest Diagnostics: Timothy Ring, Daniel Stanzione, Vicky Gregg

Quest Diagnostics announced Timothy Ring will replace Daniel Stanzione as the company's lead independent director, following the annual meeting and subject to Ring's reelection to the board. Stanzion is stepping down from the board, on which he has served since 1997. He became Quest's first lead independent director on 2003. Ring is the former chairman and CEO of CR Bard. Also, Vicky Gregg will take over as chair of the compensation committee, replacing Ring, subject to her reelection. Gregg is the former CEO of Blue Cross Blue Shield of Tennessee.

Feb 23, 2021

Ortho Clinical Diagnostics: Evelyn Dilsaver

Ortho Clinical Diagnostics has appointed Evelyn Dilsaver as a member of its board of directors and chair of its audit committee. From 2004 to 2007, Dilsaver served as the president and CEO of Charles Schwab Investment Management, the mutual fund arm of Charles Schwab, and helped grow the business from $132 billion to more than $200 billion in assets. She also served in leadership roles at Schwab for more than 16 years, including controller and chief of staff to the co-CEO. Dilsaver began her career at Ernst & Young, where she specialized in the banking and savings and loan industries.

Feb 23, 2021

Co-Diagnostics: Brian Brown, Jesse Montgomery, Reed Benson, Brent Satterfield

Co-Diagnostics has appointed Brian Brown as its CFO and Jesse Montgomery as its chief scientific officer (CSO). Co-Diagnostics' former CFO Reed Benson will remain with the company as its general counsel. Further, Brent Satterfield, the firm's founder and former CSO, will continue to be involved as the head of its scientific advisory board. Brown previously held the roles of CFO, vice president of accounting and investor relations, and director of finance for public and private companies.

Feb 23, 2021

Quotient Limited: Manuel Mendez

Quotient Limited has appointed Manuel Mendez its CEO, replacing Franz Walt, who is retiring after serving as CEO since 2018. Mendez has more than 30 years of experience in the diagnostics and life science spaces and was previously at Quest Diagnostics where he was SVP and chief commercial officer. Before that, he was SVP and head of global commercial operations at Qiagen where he was also a member of its executive committee. He has also held senior leadership positions at Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and BioMérieux.

Feb 23, 2021

Qiagen: Thomas Ebeling

Thoms Ebeling has been appointed to Qiagen's supervisory board. Ebeling has been an advisor in recent years to various companies after having served as CEO of German media group ProSiebenSat.1 from 2009 to 2018. Prior to that he worked for Novartis from 1997 to 2008, including as CEO of Novartis Pharmaceuticals and CEO of Novartis Consumer Health. Ebeling has also previously served on the supervisory boards of Bayer and Lonza.

Feb 22, 2021

Aspira Women's Health: Nicole Sandford

Aspira Women's Health has appointed Nicole Sandford to its board of directors. She was previously the executive vice president and global board services leader at Ellig Group, and prior to that Sandford was at Deloitte from 1993 to 2020, most recently as the national managing partner for its regulatory and operational risk practice.

Feb 19, 2021

Siemens Healthineers, Centogene: Peer Schatz

Peer Schatz was elected to the supervisory board of Siemens Healthineers on Feb. 12 at the company's annual shareholders' meeting. The company proposed his addition to the board on Jan. 5.

In addition, Schatz has become chairman of the supervisory board of Centogene, effective Jan. 1, 2021, after having joined the board last summer. He replaced Flemming Ornskov, who was chairman from April 1, 2019 until Dec. 31, 2020.

Schatz is the former CEO of Qiagen, a position he held from 1993 until 2019. He is currently managing director of PS Capital Management and is chairman of the board and cofounder of spatial genomics startup Resolve Biosciences. Before Qiagen, he had various roles at ComputerLand and at Sandoz and cofounded several startup companies in the IT industry. Schatz holds an master's degree in finance from the University of St. Gallen and an MBA from the University of Chicago Graduate School of Business.

Feb 19, 2021

Myriad Genetics: Kevin Haas, Faith Zaslavsky

Myriad Genetics has promoted Kevin Haas and Faith Zaslavsky. Haas, will be Myriad's new chief technology officer and report to CEO Paul Diaz. He has held various senior level positions in R&D, bioinformatics, engineering, and technology since joining the company in 2013. Zaslavsky will be president of the Myriad Oncology business unit, which she has been general manager of since 2019.

Feb 18, 2021

Infinity BiologiX: Shareef Nahas, Sameer Kalghatgi

Infinify BiologiX (IBX) has named Shareef Nahas as vice president of global laboratory operations and clinical services and interim CSO, and Sameer Kalghatgi as senior director of laboratory operations.

Nahas will report to Robin Grimwood, president and interim CEO of IBX. Nahas and Grimwood assume their interim roles following the recent passing of Andrew Brooks. Nahas was previously senior director of operations at Rady Children's Institute of Genomic Medicine in San Diego. Prior to that he held a number of senior laboratory roles at Genoptix (Novartis) and Ambry Genetics. He received his PhD in molecular toxicology from the University of California, Los Angeles.

Kalghatgi joins IBX from Coriell Institute for Medical Research, where he served as director of laboratory operations. He will report to Nahas at IBX.

IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020. Its COVID-19 saliva test was the first to receive US Food and Drug Administration Emergency Use Authorization. The company primarily provides sample collection, processing, storage, and analytical services to research and clinical customers.

Feb 18, 2021

Delfi Diagnostics: Tara Maddala, Allison Ryan

Delfi Diagnostics has appointed Tara Maddala as its VP of clinical development and Allison Ryan as VP of data science. Maddala previously served as VP of biostatistics and data managment at Grail. Ryan previously served as VP of data science at Natera.